Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Het jaar van de waarheid
Volgen
Weet iemand of er een officiele datum is wanneer de resultaten bekend gemaakt gaan worden? Ik denk dat 20 maart enekel een gerucht is of kwam dit uit de mond van JFM? Wat zou het zijn als volgende week dinsdag een PB wordt verstuurd..
Het lijkt hier net als op de beurs! Gisteren gingen we omhoog en vandaag gaan we omlaag! Nee serieus, natuurlijk is een dag als deze zwaar balen maar begin deze week stonden we nog net iets lager, zo erg is het dus ook weer niet.
@ out of the blue schreef op 6 maart 2015 16:06 :
Het lijkt hier net als op de beurs! Gisteren gingen we omhoog en vandaag gaan we omlaag! Nee serieus, natuurlijk is een dag als deze zwaar balen maar begin deze week stonden we nog net iets lager, zo erg is het dus ook weer niet.
het gaat om de trend die gezet wordt.. Met deze onstabiliteit duiken we de 50-52 range in en dan kan het enorm volatiel gaan worden. Zo dicht bij de resultaten is om extra chaos vragen..
Genfitnew schreef op 6 maart 2015 15:07 :
[...]
Echt een k*t actie van ODDO. Geen probleem met zijn rapport enkel de timing. Meer votaliteit in een volatieler aandeel.;
Hij beweert trouwens dat het eindpunt van de studie; NASh reversal; betekend dat lever geen NASH meer vertoont. Heb dit zelf nooit zo geinterpreteerd. Dacht enekel een significant verschil met placebo
Ik acht het heel goed mogelijk dat ze bewust wat verwarring aan het zaaien zijn om zelf nog wat goedkoop te kunnen inslaan (en anderen) en kijken hoe de markt reageert immers ze hebben zichzelf al ingedekt als het verhaal niet klopt
Ik blijf het een vreemde move van oddo vinden om vlak voor de bekend making van de resultaten om nog allerlei berichten de wereld in te slingeren en hun visie aantepassen Ik mag ervan uitgaan dat ze over de zelfde informatie beschikken als iedere andere buitenstaander en dat die voor iedereen toegankelijk is (of ze beschikken over voorkennis) volgens mij zetten ze hiermee hun eigen reputatie op het spel en hebben ze wel wat uitteleggen tzt Ik zie het steeds vaker bij zogenaamde deskundigen (analisten) dat ze steeds meer reageren op de waan van de dag (politici hebben daar ook een handje van) zonder een gedegen onderbouwing en een visie voor de toekomst
Staat wel een leuk artikel op het frans forum onder kopje artikel wist
Genfit: Pivotal Phase IIb Data On NASH Offers High Risk/Reward Trade Mar. 6, 2015 7:37 AM ET | 4 comments | About: Genfit (GNFTF), Includes: GILD, ICPT, SAN, SNY Subscribers to SA PRO had an early look at this article. Learn more about PRO » Disclosure: The author is long GNFTF. (More...) Summary This ICPT competitor is developing a potential best-in-class drug for treatment of NASH. Key Phase II results due by end of March could cause the stock to double. GNFTF could become leader in growing, unserved NASH market. (Editor's Note: Investors should be mindful of the risks of transacting in securities with limited liquidity, such as GNFTF. Genfit S.A. trades with more liquidity on the Paris exchange as GNFT.PA.) Useful links: Company website Company presentation (all pictures, except when specified otherwise, come from this presentation and belong solely to Genfit S.A) Deutsche Bank Small/Midcap Biotech Report (click to enlarge) INTRODUCTION Genfit (OTCPK:GNFTF) is a French biopharmaceutical company focused on the development of therapeutic and diagnostic solutions for unmet patient needs in metabolic and inflammatory diseases such as Non-Alcoholic Steato-Hepatitis . The company is "focused on contributing to bringing new medicines to market for patients with serious diseases whose treatment options are limited or non-existent." (Genfit.com). In order to achieve this goal, the company has developed a pipeline of several drug candidates, which it believes could become leaders in major markets that currently have no viable treatment options. The most advanced of these candidates, GFT505, is positioning itself as a potential best-in-class treatment for NASH, a growing, unmet condition that affects approximately 12 percent of American adults. GFT505 just completed a pivotal Phase IIb study on 275 patients worldwide, and the company will receive the statistical analysis of the results on March 10th. The results will then be made public by the end of the month, or in the first weeks of April at the latest. These results are critical because if they meet or exceed expectations, GFT505 would become the most clinically advanced NASH treatment and could quickly move into Phase III with Subpart-H designation for accelerated commercialization. These results offer the potential for a very high risk/reward trade, which could lead to a double or a halving of the share value. Per comparison, when Intercept Pharmaceuticals (NASDAQ:ICPT) announced fairly good Phase IIb results for its NASH drug candidate OCA, its share price skyrocketed from $72 to $445 over two days. In this article, I will try to demonstrate the superior profile of GFT505 against competing drug candidates, and why I think Genfit's Phase IIb results will exceed expectations. The imminent release of those results offers risk-tolerant investors the potential for a phenomenal trade, and could be played with a reasonable amount of one's portfolio. Beyond this event-driven trade, I am strongly convinced Genfit of the potential that lies in GFT505, and I believe the company will experience stupendous growth in the coming years. I am personally long the stock in anticipation of the results, as well as for the longer-term, with a twelve-month price target of €146. COMPANY OVERVIEW MM. Jean-François Mouney (CEO) and Bart Staels founded Genfit in 1999 in Lille, France. It is located at the heart of the Eurasanté Bio Business Park, an innovation center home to 134 companies and their 17,000 employees, as well as over 12,000 students. The company also has a subsidiary in Cambridge, MA in order to be close to the FDA and the American NASH market. Genfit is currently running six development programs for metabolic and inflammatory diseases. In this article, I will focus on GFT505, which is the main driver of the stock's value and offers the biggest catalyst in the coming weeks, and only cover the other programs briefly. The company was introduced to the Alternext market in December 2006, and more recently to the Euronext market, and has experienced a sizeable appreciation in 2014 after vegetating for a few years. In 2014, the stock rose from €9 to €37.68 (+318.6%). The year-to-date return so far has also been astonishing, with a 59 percent increase to €60 after hitting a high over €70 in February. This performance shows investors' appetite for companies developing NASH treatments, and gives an idea of the stock's upside and downside potential when the pivotal results become known in a few weeks. I believe the stock should trade between €70-€80 before the results are published, and depending on their quality, could be good for a 100%+ increase or a 50%+ decrease. This compares with a closing price of €60 as of February 27th. I am personally long the stock, and I will lay my bull case for Genfit after a quick explanation of what NASH is. NON-ALCOHOLIC STEATO-HEPATITIS Non-Alcoholic Steato-Hepatitis (NASH) is a fairly common disease with fast-growing prevalence around the world. Because it is a "silent" disease, many people who are in the disease's early stage are not aware that they are ill and are not diagnosed soon enough. It currently affects about 12 percent of the American adult population, and this number is bound to increase in the future as the disease is linked with obesity and diabetes. The only viable means of diagnosing NASH is via a liver biopsy, which is a very unpleasant procedure in which a doctor uses a needle to sample a small part of the liver and analyze it. This means that the market for NASH not only needs a viable treatment; it could also use easier diagnosis techniques that don't require a biopsy. (click to enlarge) NASH causes accumulation of fat in the liver, liver inflammation, degeneration of hepatocytes, and fibrosis. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) "The progression of NASH can take years, even decades. The process can stop and, in some cases, reverse on its own without specific therapy. Or NASH can slowly worsen, causing scarring or "fibrosis" to appear and accumulate in the liver. As fibrosis worsens, cirrhosis develops; the liver becomes seriously scarred, hardened, and unable to function normally." (niddk.nih.gov) This makes NASH a very preoccupying condition, and explains why the FDA has given GFT505 fast-track designation. This will make clinical development faster and easier, and when Genfit manages to bring to market a safe, effective treatment for this pathology, selling it should not be the hardest part. I will now examine the clinical profile of GFT505 and explain why I think it is superior to ICPT's Obethicolic Acid (OCA) on both effectiveness and safety. GFT505 GFT505 is a PPARa/d agonist, a drug that acts on the Peroxisome Proliferator-Activated Receptors (PPARs). PPARs "are a group of nuclear receptor proteins that function as transcription factors regulating the expression of genes." (Wikipedia.org). By controlling gene expression, PPAR agonists can be used for the treatment of metabolic diseases such as NASH. According to the company's annual report, "GFT505 is the most advanced component of a group of proprietary drug candidates historically developed by GENFIT so as to take charge of cardiovascular and metabolic diseases in groups of people suffering from a metabolic syndrome, among them, obese people, pre-diabetics and diabetics." The product, patented until 2035, should be ready to enter Phase III in the third quarter of this year if the results of the pivotal Phase IIb meet or exceed expectations.
The study was conducted on 275 patients over 52 weeks, with a daily administration of two concentrations of GFT505 (80 and 120 mg). The primary endpoint is a reversal of histological NASH without worsening of fibrosis, as well as no safety concern. In addition, if GFT505 demonstrates an improvement in fibrosis, it would be a groundbreaking achievement and a significant advantage over OCA. Only 12 percent of patients opted out of the study compared to expectations of 25 percent, which is a very good sign, especially since the treatment involves two liver biopsies, at the beginning and end of the trial, which are very cumbersome processes. Furthermore, in October 2013, "The members of the DSMB unanimously concluded that, after more than 6 months of treatment at the dose of 80 mg/day, GFT505 shows no safety issue that compromises the continuation of the Phase IIb study." This unanimous recommendation to continue the study shows that the experts were confident on the safety profile of GFT505, and that there should not be any bad surprise on this concern when the full results are made available. (click to enlarge) This picture from the company's latest presentation gives a nice snapshot of the properties of GFT505 and how they apply to the treatment of NASH. The molecule also demonstrates very strong antifibrotic activity, which represents a great potential for the treatment of non-hepatic fibrotic diseases, in addition to the beneficial effects on NASH patients. Before this pivotal trial, several other trials have been performed on GFT505 on mice, monkeys, as well as humans and showed very promising results. Genfit's molecule has consistently showed improvements in markers of inflammation and liver dysfunction, as we can see on this slide from the GFT505 presentation: (click to enlarge) In an April 14, 2014 press release, Genfit released additional data that supported the strong anti-fibrotic properties of GFT505, and its ability to reverse established fibrosis therefore enabling liver regeneration. Dr Dean Hum, Genfit's CSO stated that "this data on the anti-fibrotic effects of GFT505 further strengthens its positioning as a first-line drug for the treatment of NASH patients, including those with the most advanced disease." So far, neither OCA nor Simtizumab have demonstrated solid anti-fibrotic properties, which gives Genfit's molecule a true advantage in the treatment of inflammatory diseases such as NASH or Crohn's disease. On Crohn's, M. Hum added "GENFIT is considering the possibility of launching a Phase 2 proof-of-concept study in Crohn's disease." In a December 16, 2014 press release, the results of a trial on rats showed that GFT505 fully prevented advanced fibrosis (stage 3) and cirrhosis (stage 4), whereas 90% of the placebo group developed such pathologies.
Furthermore, 91% of the control group developed NASH while only 25% of the GFT505 group did at the end of the period. Based on these results, Genfit's CSO declared that "This study alone meets all the criteria for an efficient NASH treatment in man, the ultimate aim being to protect patients from severe hepatic complications that can lead to liver transplantation or death." The absence of safety concerns is a major plus, and was recently confirmed again after a safety study on 168 healthy volunteers was performed with daily doses between 120 mg and 300 mg (2.5 times the therapeutic dose). The results, published on January 6th, 2015, showed that GFT505 had no effect on cardiac electric activity, even at the highest doses. What is important in these results is that Genfit considers the therapeutic doses at 120 mg, whereas it used to view it as 80 mg. This could mean that GFT505 is proving effective, and that its proven safety allows for a more concentrated dosage. Deutsche Bank Securities issued an update on the stock in December 2014, and they have laid down several scenarios for the results, which are as follows (price basis: €44) As we can see, the probability of success attributed to this trial is much higher that the average 45% rate at 70%. Furthermore, I believe the "BEAR1" case is irrelevant, as GFT505 has consistently proven its safety profile, even at more than two times the therapeutic dose. Therefore, the "BEAR2" case would be my worst-case scenario and if the product were to miss the study's primary endpoint, the stock would be worth less than €30/share, which translates into a 50% decline. I also believe there are higher chances to witness a statistically significant improvement in fibrosis: whereas DBS believes it has only a 10% of occurring, I would assign odds of 20% to the super bull case, which could propel the stock to a valuation closer to that of ICPT. I believe €150 is a reasonable objective for the super bull case. I stand with DBS on the 70% probability for the base case, and I believe these results could cause a 100% increase to the €120 level. This leaves a 10% probability for the BEAR2 case, and on this basis, trading the results offers an attractive risk/reward ratio. These price targets rest on a valuation between €3 and 4 billion in the bull case and €600-800M for the bear case, based on the valuation of Genfit's closest competitor Intercept Pharmaceuticals. Even though its valuation currently hovers around $6B, it would not be reasonable to assume a similar valuation for Genfit as European biotech valuation metrics are not as high as their American counterparts. This is why I believe a valuation between €3 and 4 billion is more likely in case of good results that would put Genfit ahead of ICPT. The company also used this trial to establish biomarkers in order to diagnose NASH in an easier way, which is necessary to replace the mandatory liver biopsy. Thanks to blind blood samples collected during the study, Genfit has tried to establish benchmarks of the disease's evolution, in order to find other ways to diagnose it. It would not be possible to determine valid biomarkers if there was no evolution in the patients' condition, because one cannot measure something when there is nothing to measure. Therefore, if Genfit managed to establish new biomarkers for NASH, the treatment must have proven effective. If the results are better than expected, Genfit will suddenly be at the forefront of NASH players and will attract interest from all the large pharmaceutical companies. The company would probably use its strong position to sign a partnership in order to finance the Phase III program and ensure it can market its drug as fast as possible. In an extraordinary shareholder meeting held on February 24th, 2015, the CEO talked about several Phase III trials that would require approximately €200M. He could have been referring to an additional Phase III trial in Crohn's disease, an inflammatory pathology that could be addressed by GFT505 if it is effective enough. He also talked about the plans for a NASDAQ IPO, which is underway and should take place in the next twelve months. One can wonder if M. Mouney would make such plans if he knew that his molecule was not effective or safe enough.
OTHER NASH CANDIDATES (click to enlarge) This picture from Genfit's presentation sums up the drug candidates for the treatment of NASH. As we can see, ICPT is slightly more advanced than Genfit, having completed its Phase IIb trial recently. The trial was performed on 283 NASH patients, using a 25 mg daily dose of OCA versus placebo. The primary endpoint was met on 45% of the OCA patients versus 21% for placebo. Around 23% of OCA patients suffered from pruritus and as many were opted out of the study by the DSMB. The DSMB also noted that OCA significantly worsened cholesterol levels, but it would appear that this trend tends to reverse after the end of the treatment. Another candidate for NASH therapy is Gilead Science's (NASDAQ:GILD) Simtizumab, currently being evaluated in a Phase IIb study on 259 patients. However, this drug is more aimed at the treatment of NASH-induced cirrhosis, rather than curing NASH at an earlier stage. Currently, Intercept is clearly leading the race, but the situation is bound to evolve in the coming weeks. If GFT505 can show significant improvement on fibrosis, and more satisfying results on histological NASH, Genfit would clearly take the leader's spot. TGFTX AND SAN/GFT-2 The TGFTX program is composed of 4 molecules currently in development for the treatment of metabolic, autoimmune, fibrotic or inflammatory diseases. These various programs are not as advanced as GFT505, and even though their current value is not significant, they are a proof that Genfit is not a one-trick pony and that the company is permanently innovating. More information about these programs is available on the company's website. The SAN/GFT-2 program is part of a collaboration agreement with Sanofi (NYSE:SNY), which was originally signed in 2011 and regularly renewed since then. Its aim is to develop molecules to correct the mitochondrial dysfunction resulting from pathologies such as Type 2 diabetes and kidney diseases. Genfit can benefit from the expertise and knowledge of a large group such as Sanofi, and the cost and risk-sharing agreement means that the company will not sink all of its resources in this project. FINANCIAL SITUATION AS OF DECEMBER 31st, 2014 At the end of FY14, the company had €76.3M in cash, up from €21M the year before, and no long-term debt. The company recorded revenues of €1.6M in 2014, which mostly came from the collaboration agreement with Sanofi . Net Loss for the year has not been published, but it should be greater than the €12.6M net loss in 2013. The large increase in cash came in part from a €49.7M private equity placement that took place in the second quarter, and was funded mostly by US institutional investors. The company also raised €5M in the first quarter and €21M in the fourth quarter. It is hard to imagine that Genfit would be able to raise that kind of capital if they were not convinced of the groundbreaking potential of GFT505. Even though this level of cash is comfortable to run the company for at least two years, it cannot cover the costs of an eventual Phase III trial of GFT505, which would have to be financed through a major partnership or a capital raise such as a secondary offering or a NASDAQ IPO. Of course, financing should not be an issue when the time comes to start a Phase III, as it would imply a much higher probability of success. INVESTMENT RISKS Investing in Genfit, like any company and especially biotech ones, is inherently very risky. The company does not have significant revenue and generate consequent net losses every year. Genfit could experience failure or delays in critical clinical trials, and end up being worth little more than the cash value of the company. The company could also run out of cash if it does not manage its expenses properly and fails to raise additional cash. Investing in Genfit before the Phase IIb results is even riskier because in case of unsatisfying results, the sell-off would be very sharp and a decline of more than 50 percent is more than possible. Therefore, this investment is only suitable for risk-seeking investors who are aware of the very speculative nature of this investment. If you like the company's profile but are too risk-averse to play the results, it could be a wiser idea to take another look at the stock 6 to 12 months from now. CONCLUSION AND RECOMMENDATION There are several indicators that point to a superiority of GFT505, which should be confirmed by the Phase IIb results due in a few weeks. I believe GFT505 has the potential to become the first marketed treatment for NASH, and reap billions of dollars of high-margin revenue. Investors' commitment over the past year shows that Genfit is not an empty shell, and that despite the sizeable return of the stock so far, most of the growth still lies ahead. The obvious confidence of management over the last months, and particularly at the Feb. 24 shareholder meeting, leads to believe that Genfit is convinced of the superiority of its GFT505. Furthermore, the coming year should be very important for the company, with a planned IPO on the NASDAQ and the possible initiation of a Phase III trial on GFT505. The company could sign a partnership before initiating this trial in order to share the costs and risks with a partner. For all these reasons, I have been long the stock since the start of the year, and my current twelve-month price target is €146, which translates into a market capitalization of €3.5B, free of any dilution.
Ik krijg het gevoel dat er iets niet klopt bij Genfit , hoop dat ik verkeerd ben...als aandeelhouder.
trachy schreef op 7 maart 2015 18:16 :
Ik krijg het gevoel dat er iets niet klopt bij Genfit , hoop dat ik verkeerd ben...als aandeelhouder.
Verklaar u nader, volgens mij is de enigste vraag die nog openstaat helpt het ook (voldoende) tegen fibrose
Heel mooi uitgebreid stuk kick. Geeft heel mooi risicos plus potentie aan Als het zo gaat lopen wat deze meneer schrijft dan is zijn 146 koersdoel te laag Helemaal met subpart h Dus dinsdag krijgen ze resultaten. Dan zullen ze pb gaan voorbereiden plus powerpoint Spannende weken zeg Zou dit stuk zelfde impact hebben als oddo? En dit keer up? Moet traden tussen 70-80 voor de cijfers Nog 15 euro omhoog dus komende weken
In de aanloop naar de resultaten zijn er nog wat partijen (Oddo) die vuile spelletjes spelen, om zelf nog zo goedkoop mogelijk aandeeltjes te kunnen inslaan.
Opstapelen schreef op 8 maart 2015 15:15 :
Heel mooi uitgebreid stuk kick. Geeft heel mooi risicos plus potentie aan
Als het zo gaat lopen wat deze meneer schrijft dan is zijn 146 koersdoel te laag
Helemaal met subpart h
Dus dinsdag krijgen ze resultaten. Dan zullen ze pb gaan voorbereiden plus powerpoint
Spannende weken zeg
Zou dit stuk zelfde impact hebben als oddo? En dit keer up?
Moet traden tussen 70-80 voor de cijfers Nog 15 euro omhoog dus komende weken
Vond het artike oppervlakkig en heel eenzijdig (Gent bekeken door de ogen van een Bull) en bevat wat fouten over de concurrenten. Je moet weten dat deze artikels geen invloed hebben op het aandeel. Kan geschreven worden door mensen zoals jij en ik. Dit worden inderdaad spannende weken. Ik haal mijn stop weg op 49eur (je weet maar nooit dat die zover zakt maar hoop natuurlijk van niet). Hopen dat er genoeg kopers zijn die in genfit geloven.
Tuurlijk een stuk geschreven vanuit de hoek van een aandeelhouder. Neemt niet weg dat een mooi uitgebreid stuk is met punten waar je over kan twisten.Maar vooral de risico's versus potentie is goed weer gegeven. Krijg sterk de indruk dat iemand weer wat lager stukken heeft opgepikt net. Na een -10% dagje verwacht je toch vandaag beetje herstel.
Genfitnew schreef op 8 maart 2015 18:26 :
[...]
Vond het artike oppervlakkig en heel eenzijdig (Gent bekeken door de ogen van een Bull) en bevat wat fouten over de concurrenten. Je moet weten dat deze artikels geen invloed hebben op het aandeel. Kan geschreven worden door mensen zoals jij en ik.
Dit worden inderdaad spannende weken. Ik haal mijn stop weg op 49eur (je weet maar nooit dat die zover zakt maar hoop natuurlijk van niet). Hopen dat er genoeg kopers zijn die in genfit geloven.
Is inderdaad verstandig om over je stop na te denken. Een koers van onder de 50 sluit ik niet meer uit. Het gaat weer hard.
Bizar hoe hard dit weer down gaat,,,kan het niet plaatsen ook.
Opstapelen schreef op 9 maart 2015 09:30 :
Bizar hoe hard dit weer down gaat,,,kan het niet plaatsen ook.
Hoe zagen de blokken eruit? shorters die alles geven, laatste week voor de week van de resultaten lol
Grote stroom verkooporders, kon niets geks ontdekken op paar dumps na. Die lijkt nu op te drogen trouwens, weer voorzichtig door de 58
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee